The global lymphoma treatment market is expected to grow at a CAGR of around 8.4% from 2020 to 2027 and expected to reach the market value of around US$ 13.3 Bn by 2027.
Lymphoma is a type of cancer that can affect the bone marrow, the blood cells, the lymph nodes, and other parts of the lymphatic system. According to the estimates released by the Leukemia & Lymphoma Society® (LLS) approx. every 3 minutes one person in the US is diagnosed with blood cancer. Additionally, an estimated combined total of 178,520 people in the US were diagnosed with lymphoma in 2020. New cases of lymphoma were recorded with 9.9% of the estimated 1,806,590 new cancer cases diagnosed in the US in 2020. An estimated 1,297,027 people in the US are either living with, or are in remission from lymphoma. Between 2000 and 2017, approx. 40% of cancer fighting therapies was approved by the FDA to treat blood cancer patients and helping patients with certain type of treatment. Rituxan® was first approved to treat lymphoma patients, is now approved to treat patients with rheumatoid arthritis and other autoimmune diseases.
Currently, Celgene Corporation has sponsored three drugs namely, “Fludarabine”, “Cyclophosphamide”, and “JCAR017” for treatment of Lymphoma for Non-Hodgkin patients. All three drugs are under clinical trials phase 2. Actual start date for preliminary examination was July 2020 and estimated completion date is April 2024. Moreover, Genmab A/S in collaboration with AbbVie has sponsored a drug name “Epcoritamab”. It can be used for treatment for Diffuse Large B-cell Lymphoma, Primary Mediastinal
Large B-cell Lymphoma, Small Lymphocytic Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma. The clinical study is under Phase 2 and actual completion date is December 2025.
Leapfrogging with lymphoma treatment
According to the statistics released by the Leukemia & Lymphoma Society® (LLS), it is estimated that 791.550 people living with, or in remission form of lymphoma in the US. There are 146,789 people living with or in remission from Hodgkin lymphoma. Also, there are 644,761 people living with or in remission from non-Hodgkin lymphoma. In February 2021, Food and Drug Administration (FDA), approved “lisocabtagene maraleucel” manufactured by the Breyanzi, Juno Therapeutics, Inc. It is used as a treatment for adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, involving diffuse large B-cell lymphoma (DLBCL). Moreover, FDA approved “crizotinib” manufactured by the XALKORI®, a registered trademark of Pfizer Inc. for pediatric patients with 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. Governing bodies like Alzheimer’s Association for affordable diagnostic test will boost the market growth of Lymphoma treatment.
Managing survival rates with effective treatments
As per the Leukemia & Lymphoma Society, lymphoma (Hodgkin Lymphoma (HL), 6.5% and Non-Hodgkin Lymphoma (NHL), 7.5% is the third most common cancer in children, adolescents, and young adults younger than 20 years. Five year relative survival is 97.6% for HL in children, adolescents, and young adults younger than 20 years. Additionally, in children, adolescents and young adults younger than 20 years, 5-year relative survival for NHL is 90.3%. The estimates show significant improvement in the rate of survival.
According to the American Cancer Society, targeted therapies have grabbed significant attention for the treatment of lymphoma. As researchers have learned about the lymphoma cells, it has enhanced the development of newer drugs that target specific parts of the lymphoma cells. These targeted drugs are different from the standard chemotherapy drugs that work by attacking rapidly growing cells. Some targeted drugs are ibrutinib (Imbruvica), acalabrutinib (Calquence), and idelalisib (Zydelig). These drugs are already used for some types of NHL and there is an ongoing study related to be used against other types.
Moving Genomics to the Clinics
In the current scenario, scientists are making a lot of progress in understanding the changes in DNA inside the normal lymphocytes that can cause to the development of lymphoma cells. One such technique is stem cell transplant. Autologous transplants (which use the patient's own stem cells rather than cells from a donor) have the risk of reintroducing lymphoma cells back into the patient after treatment. However, researchers are testing new and improved methods to separate out the last traces of lymphoma cells from the stem cells before they are returned to the patient. Some of the new monoclonal antibodies developed for treating lymphoma may assist in removing these remaining cells.
Apart from that, researchers are also conducting studies for effectiveness of non-myeloablative (reduced-intensity) stem cell transplants in people with lymphoma. Another technique is chimeric antigen receptor (CAR) T-cell therapy. In this treatment, immune cells called the T-cells are removed from the patient's blood and altered in the lab to specific receptors (called chimeric antigen receptors, or CARs) on their surface. These receptors can be attached to proteins on the surface of lymphoma cells and launch a precise immune attack against them. Such CAR T-cell therapy approved are Axicabtagene ciloleucel (Yescarta), Tisagenlecleucel (Kymriah), Lisocabtagene maraleucel (Breyanzi, also known as liso-cel), and Brexucabtagene autoleucel (Tecartus)
Lymphoma treatment market is segmented into type, drug and region. Based on type, it is bifurcated into Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). By drug, the lymphoma market is segmented as adcetris, rituxan/mabthera, imbruvica, keytruda, revlimid, and among others.
By type, NHL will hold the largest market share in the forecast period. This is attributed to presence of established drugs such as Revlimid, Rituxan, and Imbruvica. These drugs are some of the biggest revenue generating oncology drugs contributing lymphoma treatment market.
On the other hand, based on drugs segment, Revlimid will be dominating segment and it is anticipated that it will hold a significant market share in the forecast period. Revlimid sales have climbed all-time high market share it is preferable as first line of prescribed drug treatment for the duration of cancer treatments.
North America Dominates the Lymphoma Treatment Market
Based on regions, North America dominates the lymphoma treatment market. This is well supported by the presence of dominating players, new drug innovations coupled with availability of new drugs, well-established healthcare infrastructure, and high R&D expenditure. Asia-Pacific is projected to witness the fastest growth in the forecast period by recording a remarkable CAGR of nearly 10.8%. Rising healthcare expenditure, increased unmet medical needs, rising awareness regarding treatment options, and availability of effective treatment in emerging economies such as China & South Korea.
Key companies profiled in this report involve Merck Sharp & Dohme Corp., Seagen Inc., Takeda Pharmaceutical Company, Johnson & Johnson Services, Inc., Lilly., Abbott., Bristol-Myers Squibb Company; Celgene Corporation, F. Hoffmann-La Roche Ltd., and among others.
Market By Type
Hodgkin Lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Market By Drug
Market By Geography
Middle East & Africa
Lymphoma treatment is expected to reach a market value of around US$ 13.3 Bn by 2027.
The lymphoma treatment market is expected to grow at a CAGR of around 8.4% from 2020 to 2027.
Drug is the leading segment in the overall market.
Innovation in treatment is one of the prominent factors that drive the demand for lymphoma treatment market.
Merck Sharp & Dohme Corp., Seagen Inc., Takeda Pharmaceutical Company, Johnson & Johnson Services, Inc., Lilly., Abbott., Bristol-Myers Squibb Company; Celgene Corporation, F. Hoffmann-La Roche Ltd., and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years